Bmy stock price – bristol-myers squibb co. stock quote (u.s. nyse) – marketwatch gas utility boston

#

In a fierce rivalry to prove cancer drug combinations work better for advanced lung cancer, Merck & Co. drew ahead of rivals on Monday, releasing late-stage results showing that a cancer drug combination using its Keytruda reduced patients’ risk of death by half, a significant improvement. Merck shares rose 3% in heavy Monday trade. Bristol-Myers Squibb also released results Monday morning for a cancer drug combination including its drugs Opdivo and Yervoy, finding that the combination improved progression-free survival with patients in a particular subgroup who had a high tumor mutational burden. Progression-free survival, which looks at how long it takes before a patient’s cancer worsens, is one measure of a cancer therapy’s success but is considered less important than overall survival, which the Merck trial measured. The odds of a patient recovering faster with the Merck treatment was 0.49, referring specifically to overall survival, while the odds for a patient on the Bristol-Myers treatment was 0.58, referring specifically to progression-free survival. Bristol-Myers shares dropped 5.7% in Monday trade, while Astrazeneca , another drugmaker working in the space, had shares fall 1.7%. The Merck results are the latest evidence supporting a trend of pairing immuno-oncology drugs, which harness the immune system to fight cancer, with other cancer treatments, including other immuno-oncology drugs, chemotherapy and radiation. Drugmakers have made big investments in this area, but experts fear it could cause the already-high prices of cancer drugs to double or triple. Merck shares have surged 8.3% month-to-date, compared with a 12.7% drop in Bristol-Myers shares and a 1.2% rise in the S&P 500 .

NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won’t proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company will instead look at the possibility of another randomized evaluation of the drug for melanoma, a decision made after "the failure of a competitor’s trial… in a similar clinical setting," NewLink said, referring to the failure of a similar drug in a Merck and Incyte trial earlier this month. The phase 3 trial, called Indigo301, aimed to test indoximod in combination with Merck’s cancer drug Keytruda or Bristol-Myers Squibb’s cancer drug Opdivo . Sunday’s NewLink announcement wasn’t unexpected, as the company previously said it planned to review its clinical programs after the Merck/Incyte trial results. More unexpected, however, was the decision to stick its news at the end of another press release, regarding early results for indoximod in pediatric progressive brain tumors. NewLink shares have dropped 38% over the last month, compared with a 0.6% rise in the S&P 500 .

In a fierce rivalry to prove cancer drug combinations work better for advanced lung cancer, Merck & Co. drew ahead of rivals on Monday, releasing late-stage results showing that a cancer drug combination using its Keytruda reduced patients’ risk of death by half, a significant improvement. Merck shares rose 3% in heavy Monday trade. Bristol-Myers Squibb also released results Monday morning for a cancer drug combination including its drugs Opdivo and Yervoy, finding that the combination improved progression-free survival with patients in a particular subgroup who had a high tumor mutational burden. Progression-free survival, which looks at how long it takes before a patient’s cancer worsens, is one measure of a cancer therapy’s success but is considered less important than overall survival, which the Merck trial measured. The odds of a patient recovering faster with the Merck treatment was 0.49, referring specifically to overall survival, while the odds for a patient on the Bristol-Myers treatment was 0.58, referring specifically to progression-free survival. Bristol-Myers shares dropped 5.7% in Monday trade, while Astrazeneca , another drugmaker working in the space, had shares fall 1.7%. The Merck results are the latest evidence supporting a trend of pairing immuno-oncology drugs, which harness the immune system to fight cancer, with other cancer treatments, including other immuno-oncology drugs, chemotherapy and radiation. Drugmakers have made big investments in this area, but experts fear it could cause the already-high prices of cancer drugs to double or triple. Merck shares have surged 8.3% month-to-date, compared with a 12.7% drop in Bristol-Myers shares and a 1.2% rise in the S&P 500 .

NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won’t proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company will instead look at the possibility of another randomized evaluation of the drug for melanoma, a decision made after "the failure of a competitor’s trial… in a similar clinical setting," NewLink said, referring to the failure of a similar drug in a Merck and Incyte trial earlier this month. The phase 3 trial, called Indigo301, aimed to test indoximod in combination with Merck’s cancer drug Keytruda or Bristol-Myers Squibb’s cancer drug Opdivo . Sunday’s NewLink announcement wasn’t unexpected, as the company previously said it planned to review its clinical programs after the Merck/Incyte trial results. More unexpected, however, was the decision to stick its news at the end of another press release, regarding early results for indoximod in pediatric progressive brain tumors. NewLink shares have dropped 38% over the last month, compared with a 0.6% rise in the S&P 500 .